Form 8-K - Current report:
SEC Accession No. 0000950170-25-104545
Filing Date
2025-08-07
Accepted
2025-08-07 07:03:17
Documents
12
Period of Report
2025-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K glue-20250807.htm   iXBRL 8-K 54830
2 EX-99.1 glue-ex99_1.htm EX-99.1 266205
3 GRAPHIC img106802192_0.jpg GRAPHIC 12665
  Complete submission text file 0000950170-25-104545.txt   472502

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20250807.xsd EX-101.SCH 30669
14 EXTRACTED XBRL INSTANCE DOCUMENT glue-20250807_htm.xml XML 4892
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)